Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 591 clinical trials
Featured trial
ATR Inhibitor BAY 1895344 plus pembrolizumab in advanced solid tumors (GI, Pancreatic, mCRPC, NSCLC)

This clinical study aims to investigate if impairment of the deoxyribonucleic acid damage repair (DDR) pathway by the Elimusertib in combination with blockade of the PD-1/PD-L1 pathway by pembrolizumab, may improve antitumor responses in advanced cancer patients with DDR aberrations, at an acceptable safety profile and an expected positive benefit/risk …

measurable disease
EGFR
pembrolizumab
  • 20 views
  • 13 Oct, 2021
  • 8 locations
Featured trial
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.  This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose …

carcinoma
metastatic cervical cancer
urothelial carcinoma
ovarian cancer
  • 380 views
  • 10 May, 2022
  • 4 locations
Featured trial
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies. This investigational intervention treatment uses a single biological drug and is conducted in two parts. Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with …

advanced cancer
cancer
  • 226 views
  • 10 May, 2022
  • 4 locations
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

"This is an international, multicenter, randomized, double-blind phase III study, plans to recruit 680 patients who received radical gastrectomy (R0, D2 or higher lymphadenectomy) with postoperative pathological stage II (T4aN0M0) or III (the 8th Edition American Joint Committee on Cancer [AJCC] Cancer Staging Manual) gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, …

  • 0 views
  • 22 Apr, 2022
  • 4 locations
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)

Fruquintinib once daily in 4 weeks treatment cycle (three weeks on and one week off) in combination with Paclitaxel 80mg/day1, 8, 15 of 4 weeks cycle) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced GC in ph1b/2 study. This study is aimed to evaluate …

  • 12 views
  • 11 Feb, 2021
  • 7 locations
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (VESTIGE)

The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3 and/or R1 status) following neoadjuvant chemotherapy and resection. Other study …

  • 33 views
  • 26 Feb, 2022
  • 20 locations
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer (Neo-D2plus)

In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC). After conclusions of NAC and obtaining informed consent, they will be registered and randomized to receive surgical D2 vs. D2plus lymphadenectomy.

  • 0 views
  • 09 Feb, 2022
  • 1 location
A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

FNF-014 is a randomised, open-label, multicentre, parallel-group, phase 3 study in China to prove superiority of POF over S-1/docetaxel in postoperative adjuvant setting for pStage III gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction).

  • 0 views
  • 07 Feb, 2022
  • 1 location
Risk of GAstric Adenocarcinoma After Cephalic Duodenopancreatectomy (RAGAD)

In view of the similarities of the surgical set-ups of partial gastrectomies and cephalic duodenopancreatectomies, and the increased risk of gastric cancer after early partial gastrectomy, it is

  • 0 views
  • 02 Mar, 2022
  • 1 location
Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy

This study aims to compare the efficacy of the current standard first-line anti-helicobacter pylori regimen, extended proton pump inhibitor-based sequential therapy, with that of vonoprazan-based triple therapy, through a randomized controlled trial.

  • 0 views
  • 23 May, 2022
  • 1 location